Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07534644) titled 'A Phase I/? Clinical Trial for HS_SW01 Cells Injection in the Treatment of Ankylosing Spondylitis' on April 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shenzhen Huishan Biotechnology Co., Ltd.
Condition:
Ankylosing Spondylitis
Intervention:
Drug: HS_SW01 cells injection
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 10, 2026
Target Sample Size: 18
To know more, visit https://clinicaltrials.gov/study/NCT07534644
Di...